e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Pathogenesis of pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Azithromycin in a bleomycin mouse model: finding the holy grail for pulmonary fibrosis?
W. Wuyts, R. Vos, B. Vanaudenaerde, S. De Vleeschauwer, M. Rinaldi, W. Janssens, M. Demedts, M. Thomeer, E. Verbeken, G. Verleden (Leuven, Belgium)
Source:
Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Session:
Pathogenesis of pulmonary fibrosis
Session type:
E-Communication Session
Number:
230
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Wuyts, R. Vos, B. Vanaudenaerde, S. De Vleeschauwer, M. Rinaldi, W. Janssens, M. Demedts, M. Thomeer, E. Verbeken, G. Verleden (Leuven, Belgium). Azithromycin in a bleomycin mouse model: finding the holy grail for pulmonary fibrosis?. Eur Respir J 2009; 34: Suppl. 53, 230
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
The impact of anti-IgE treatment on the airway microbiome in asthma.
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Related content which might interest you:
Combined pulmonary fibrosis and emphysema: bad and ugly all the same?
Source: Eur Respir J, 50 (1) 1700846; 10.1183/13993003.00846-2017
Year: 2017
Prognostic staging of acute pulmonary embolism: are we closer to the holy grail?
Source: Eur Respir J 2014; 44: 565-567
Year: 2014
Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard
Source: Eur Respir J 2015; 45: 1208-1210
Year: 2015
Treatable traits: a step closer to the “holy grail” of asthma control?
Source: Eur Respir J, 55 (3) 2000002; 10.1183/13993003.00002-2020
Year: 2020
Opening Lecture: Is human pulmonary fibrosis simply lung regeneration without a blueprint?
Source: ERS Lung Science Conference 2021
Year: 2021
The therapy of idiopathic pulmonary fibrosis: what is next?
Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019
Year: 2019
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Revisiting α1-antitrypsin therapy in cystic fibrosis: can it still offer promise?
Source: Eur Respir J 2007; 29: 229-230
Year: 2007
What have we learned from basic science studies on idiopathic pulmonary fibrosis?
Source: Eur Respir Rev, 28 (153) 190029; 10.1183/16000617.0029-2019
Year: 2019
Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1218-1220
Year: 2015
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Combined pulmonary fibrosis and emphysema: A distinct entity?
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
Late Breaking Abstract - MIF inhibition in a murine model of bleomycin-induced lung fibrosis
Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension
Year: 2018
Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?
Source: Eur Respir J, 55 (6) 2000811; 10.1183/13993003.00811-2020
Year: 2020
Epithelial pIgR: A new player in idiopathic pulmonary fibrosis?
Source: International Congress 2018 – New kids on the block: novel molecular pathways and therapeutic targets in chronic lung diseases
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept